Scilex unit ACEA Therapeutics agrees to sell ACEA Pharma to Phoenix Asia for $1 billion
PUBT · 16h ago
Share
Listen to the news
- Scilex indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in exchange for 100,000,000 newly issued Phoenix ordinary shares priced at USD 10 each, valuing consideration at USD 1 billion.
- Phoenix plans to rename itself ACEA Pharma, with common stock expected to be listed on Nasdaq.
- Closing is targeted by end of Q2 2026, with ACEA Therapeutics expected to own about 82% of go-forward company upon completion.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scilex Holding Company published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved